Stephen Willingham, Ph.D.

Affiliations: 
2007 Genetics & Molecular Biology University of North Carolina, Chapel Hill, Chapel Hill, NC 
Area:
Neuroinflammation
Google:
"Stephen Willingham"
Mean distance: 19.07 (cluster 11)
 

Parents

Sign in to add mentor
Jenny P-Y Ting grad student 2007 UNC Chapel Hill
 (Microbial pathogen-induced necrosis mediated by NLRP3 and ASC.)
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Krampitz GW, George BM, Willingham SB, et al. (2016) Identification of tumorigenic cells and therapeutic targets in pancreatic neuroendocrine tumors. Proceedings of the National Academy of Sciences of the United States of America
Liu J, Wang L, Zhao F, et al. (2015) Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential. Plos One. 10: e0137345
Huang W, Seo J, Willingham SB, et al. (2014) Learning from host-defense peptides: cationic, amphipathic peptoids with potent anticancer activity. Plos One. 9: e90397
Earhart CM, Hughes CE, Gaster RS, et al. (2014) Isolation and mutational analysis of circulating tumor cells from lung cancer patients with magnetic sifters and biochips. Lab On a Chip. 14: 78-88
Edris B, Willingham S, Weiskopf K, et al. (2013) Use of a KIT-specific monoclonal antibody to bypass imatinib resistance in gastrointestinal stromal tumors. Oncoimmunology. 2: e24452
Tseng D, Volkmer JP, Willingham SB, et al. (2013) Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response. Proceedings of the National Academy of Sciences of the United States of America. 110: 11103-8
Edris B, Willingham SB, Weiskopf K, et al. (2013) Anti-KIT monoclonal antibody inhibits imatinib-resistant gastrointestinal stromal tumor growth. Proceedings of the National Academy of Sciences of the United States of America. 110: 3501-6
Kim D, Wang J, Willingham SB, et al. (2012) Anti-CD47 antibodies promote phagocytosis and inhibit the growth of human myeloma cells. Leukemia. 26: 2538-45
Edris B, Weiskopf K, Volkmer AK, et al. (2012) Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcoma. Proceedings of the National Academy of Sciences of the United States of America. 109: 6656-61
Willingham SB, Volkmer JP, Gentles AJ, et al. (2012) The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proceedings of the National Academy of Sciences of the United States of America. 109: 6662-7
See more...